Get the app!
Back to Trades
Total Value
$536.6K
Net $203.8K sold
Filing Date
Jul 25, 2025
2 transactions
Sales
$203.8K
2 transactions

Trade Summary

On Jul 23, 2025 through Jul 24, 2025, AULT MILTON C III, Insider, sold $536.6K of Alzamend Neuro, Inc. (ALZN) across 2 transactions. The filing covers Common Stock and reflects net selling of $203.8K. Reported prices ranged from $2.32 to $2.95. Insider transactions are sourced from SEC Form 4 disclosures and should be reviewed alongside company fundamentals and the insider's broader trading history.

Company Information

Ticker Symbol
ALZN
CIK
0001677077

Insider Information

Role
Insider
Location
LAS VEGAS, NV

Filing Details

Filing Date
Jul 25, 2025
Transaction Date
Jul 23, 2025
Accession Number
0001214659-25-010933
Form Type
4
Net Trading Amount
-$203.8K

Non-Derivative Transactions

DateSecuritySharesPriceTypeValue
Jul 23, 2025Common Stock143,429$2.32C$332.8K
Jul 23, 2025Common Stock59,516$2.95Sale$175.6K
Jul 24, 2025Common Stock9,621$2.93Sale$28.2K

Derivative Transactions

DateSecuritySharesExercise PriceTypeValue
Jul 23, 2025ALZN derivative332.755C

Want live alerts when AULT MILTON C III trades again?

Download Insider Trades to track ALZN, follow insiders, and get mobile alerts when new SEC Form 4 filings are published.

Footnotes

  1. (F1)Represents shares of common stock received upon conversion of Series B convertible preferred stock ("Series B Preferred").
  2. (F2)Ault Lending, LLC ("Ault Lending"), is a wholly-owned subsidiary of Hyperscale Data, Inc. ("HSD"). Mr. Ault, the Executive Chairman of HSD, is deemed to have voting and investment power with respect to the securities held of record by Ault Lending.
  3. (F3)Mr. Ault has sole voting and investment power with respect to the securities held of record by Ault Life Sciences, Inc.
  4. (F4)Mr. Ault has sole voting and investment power with respect to the securities held of record by Ault Life Sciences Fund, LLC.
  5. (F5)The Conversion Price of the Series B Preferred is subject to adjustment as set forth in that certain of Designation of Preferences, Rights and Limitations of the Series B Convertible Voting Preferred Stock.
  6. (F6)The shares of Series B Preferred have no expiration date.
  7. (F7)Mr. Ault, the Executive Chairman of HSD, is deemed to have voting and investment power with respect to the securities held of record by HSD.

SEC Filing

View on SEC Daily

View the complete filing document on SEC Daily.